Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06539637 · ClinicalTrials.gov registry record · Early Phase 1
Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%
A Early Phase 1 study of Cataract, sponsored by DHS Consulting.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06539637: Recruiting Early Phase 1 study of Cataract, sponsored by DHS Consulting.
NCT06539637 is a Early Phase 1 study of Cataract that is actively recruiting participants, run by DHS Consulting. The registered enrollment target is 20 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06539637, a Early Phase 1 study of Cataract, is actively recruiting participants, sponsored by DHS Consulting.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a clinical trial evaluating Ketorolac levels in vitreous and aqueous humor samples from patients undergoing combined cataract and pars plana vitrectomy surgeries with and without intracameral phenylephrine 1.0% / ketorolac 0.3% (OMIDRIA). Patients not receiving intracameral OMIDRIA will receive topical ketorolac prior to cataract surgery/pars plana vitrectomy.
Conditions Studied
Interventions
- COMBINATION_PRODUCT OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}
- OTHER Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Study Locations (1)
New York
- Ophthalmic Consultants of Long Island - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2026-02 |
| Phase | Early Phase 1 |
What NCT06539637 shows while recruiting
NCT06539637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac} is the first listed.
NCT06539637 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06539637 about?
NCT06539637 is a clinical study titled "Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%". This is a clinical trial evaluating Ketorolac levels in vitreous and aqueous humor samples from patients undergoing combined cataract and pars plana vitrectomy surgeries with and without intracameral phenylephrine 1.0% / ketorolac 0.3% (OMIDRIA). Patients not receiving intracameral OMIDRIA will rece...
What is the current status of trial NCT06539637?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2023-09-01. Estimated completion is 2026-02.
What conditions does trial NCT06539637 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT06539637?
The interventions under investigation include: OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac} (COMBINATION_PRODUCT), Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop (OTHER).
Who is sponsoring clinical trial NCT06539637?
This trial is sponsored by DHS Consulting, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06539637 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06539637's enrollment target sits among peer trials
20 79th of 83 higher than 2 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
COMPLETED · Early Phase 1
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI